Call Us Free: (800) 394-2767

Viewpoint: China has the upper hand in cancer cell therapy

Cheers went up last August when the U.S. Food and Drug Administration approved the world’s first CAR-T cancer cell treatment, Novartis’ Kymriah, and again in October when it approved Gilead’s CAR-T treatment for non-Hodgkin’s lymphoma. In CAR-T therapy, the immune system’s killer T cells are modified to target specific tumors, giving physicians a powerful new tool to treat cancer.

But when it comes to the long-term development of this revolutionary treatment, China is poised to leapfrog…

Source link

Leave a Reply